Welcome to our dedicated page for Relay Therapeutics news (Ticker: RLAY), a resource for investors and traders seeking the latest updates and insights on Relay Therapeutics stock.
Relay Therapeutics, Inc. (Nasdaq: RLAY) is a clinical-stage biotechnology company pioneering drug discovery through its Dynamo™ platform, which analyzes protein motion to develop precision therapies for oncology and genetic diseases. This page provides real-time access to official company announcements, research breakthroughs, and strategic developments.
Investors and industry professionals will find curated updates including clinical trial progress, regulatory milestones, and partnership announcements. All content is sourced directly from Relay Therapeutics’ communications and verified financial disclosures, ensuring reliability for decision-making.
Key coverage areas include innovations in small molecule therapeutics, updates on the Dynamo platform’s applications, and analyses of Relay’s position within the precision medicine landscape. Content is organized chronologically for easy tracking of the company’s evolution.
Bookmark this page to monitor Relay Therapeutics’ advancements in targeting historically undruggable proteins. For comprehensive insights into RLAY’s scientific and corporate developments, revisit regularly or subscribe to Stock Titan’s update alerts.
Relay Therapeutics, Inc. (Nasdaq: RLAY) is set to participate in two fireside chats, enhancing its visibility in the oncology and healthcare sectors. The events are scheduled for:
- Stifel 2023 Targeted Oncology Days on April 26, 2023, at 12:30 p.m. ET
- BofA Securities 2023 Health Care Conference on May 9, 2023, at 10:00 a.m. PT
Both discussions will be webcast live, accessible on Relay Therapeutics’ website, with archived replays available for 30 days post-event. Relay Therapeutics is a clinical-stage precision medicine company dedicated to revolutionizing drug discovery through innovative computational and experimental technologies, focusing on small molecule therapeutic discovery in oncology and genetic diseases.
Relay Therapeutics (Nasdaq: RLAY) announced promising initial clinical data for RLY-2608, an investigational allosteric PI3Kα inhibitor. The data demonstrated sustained target exposure of over 80% in mutant PI3Kα inhibition across various doses. Notably, no Grade 3 hyperglycemia, rash, or diarrhea, common treatment discontinuation events, were observed. A confirmed partial response was recorded in a breast cancer patient with extensive prior therapies. The ongoing ReDiscover trial, which began in December 2021, aims to evaluate this drug's safety and efficacy in patients with unresectable or metastatic solid tumors. Relay plans to initiate expansion cohorts in the second half of 2023. The results suggest RLY-2608 could transform treatment for patients with diverse PI3Kα mutations and improve the therapeutic index of PI3Kα inhibitors.
FAQ
What is the current stock price of Relay Therapeutics (RLAY)?
What is the market cap of Relay Therapeutics (RLAY)?
